


## Breakthrough Science to Increase Healthy Lifespan

CohBar is a preclinical stage biotechnology company focused on the research and development of mitochondria based therapeutics (MBTs), an emerging class of drugs for the treatment of age-related diseases. MBTs originate from the discovery by CohBar’s founders of a novel group of peptides within the mitochondrial genome which regulate metabolism and cell death, and whose biological activity declines with age. CohBar’s efforts are focused on the development of these mitochondrial-derived peptides into clinically relevant therapeutics with the potential to address a broad range of age-related diseases, including obesity, nonalcoholic steatohepatitis (NASH), type-2 diabetes, cancer, and cardiovascular and neurodegenerative disorders.


## CohBar Therapeutic Source – The Mitochondria, a Central Role in Metabolism



- Mitochondria, the powerhouses of the cell, produce energy (ATP), regulate cellular metabolism and have their own genome (mtDNA)
- mtDNA encodes biologically active peptides that have been conserved through human evolution
- CohBar and its founders have discovered more than 50 biologically active mitochondrial-derived peptides
- In preclinical disease models, these peptides’ potential therapeutic effects include metabolic regulation and neuro-protective, cyto-protective and anti-inflammatory activity

## Major Age-Related Diseases Share Common Biology of Metabolic Dysfunction

- **Obesity:** associated with T2D, coronary heart disease, stroke, hypertension and cancer, over 90% of obese adults may have non-alcoholic fatty liver disease (NAFLD)
- **NASH:** as many as 12% of US adults may have non-alcoholic steatohepatitis (NASH), 70-90% of NASH sufferers are morbidly obese or have type 2 diabetes (T2D)
- **Pre-diabetes/Diabetes:** 9% of US adult population estimated to have T2D, obesity and age are major risk factors
- **Therapeutic Market Size Estimates (Annual US):** NASH – up to \$40B (currently no approved drugs), T2D \$40B, Obesity \$4B




Sources: Company data, CDC, NIH, WHO, World Journal of Gastroenterology, American Diabetes Association, Diabetes Management, Journal of Clinical Endocrinology and Metabolism, American Society for Metabolic and Bariatric Surgery.

## CohBar Clinical Development Program

| Target Indication                         | Preclinical | IND Enabling Activities & Confirmatory Studies | Phase 1 |
|---|-------------|--|---------|
| <b>MOTS-c Analogs CB4209 &amp; CB4211</b> |             |  |         |
| Obesity                                   | ██████████  |  |         |
| NASH                                      | ██████████  |  |         |
| Type 2 Diabetes                           | ██████████  |  |         |
| <b>SHLP6</b>                              |             |  |         |
| Cancer                                    | ██████████  |  |         |
| <b>SHLP2</b>                              |             |  |         |
| Type 2 Diabetes/ Alzheimer's              | ██████████  |  |         |
| <b>New MDPs</b>                           |             |  |         |
| Multiple Age Related Diseases             | ██████████  |  |         |

- CB4209 and CB4211 are optimized analogs from CohBar’s MOTS-c program which have demonstrated a role in regulating metabolism as well as therapeutic potential in preclinical models for obesity and NASH, with additional investigation ongoing to determine therapeutic potential as an adjunct for T2D
- CohBar’s expanding family of over 50 peptides, including licensed compounds SHLP6 and SHLP2, are being evaluated for potential to treat wide range of age-related diseases, both for internal development and partnership opportunities

## CohBar Platform Technology – Development of Mitochondria Based Therapeutics



CohBar’s proprietary platform technology explores the mitochondrial genome for new peptides that exhibit biological activity, and optimizes their structures using cell based and preclinical models to deliver proprietary therapeutics with the potential to treat a wide range of age-related diseases.

### Investment Highlights

- A leader in the emerging field of **mitochondria based therapeutics** to treat major age-related diseases
- Preclinical pipeline of drug candidates with **therapeutic potential to treat multiple diseases**
- Target indications with **large markets needing safer, more effective drugs**
- Ongoing IND-enabling studies to support **initial clinical testing in early 2018**
- Total of **\$22.8 million** in funding raised from Series B offering, TSXV IPO in January 2015 and warrant exercises through January 2017
- SEC reporting company, traded on **OTCQX (CWBR)** in the US and **TSXV (COB.U)** in Canada
- Cash balance as of September 30, 2016: **\$8.1 million** (with subsequent warrant funding in January 2017)
- Shares outstanding as of January 2017: **35.8 million**
- Founders, Board and Management own **41% of the equity**
- Market capitalization as of January 31, 2017: **\$82 million**

### Founders

**Nir Barzilai, M.D. (Founder and Director):** Professor of Genetics and Director of the Institute for Aging at the Albert Einstein College of Medicine. Nathan Shock and Ellison Foundation award recipient.

**Pinchas Cohen, M.D. (Founder and Director):** Dean of the Davis School of Gerontology at the University of Southern California. National Institute for Aging Eureka award winner.

**David Sinclair, PhD. (Co-Founder):** Professor of Genetics at Harvard Medical School and Founder of Sirtris Pharma and OvaScience.

**John Amatruda, M.D. (Co-Founder):** Former SVP and Franchise Head for Diabetes and Obesity at Merck Research Laboratories

### Management Team

**Simon J. Allen MBA (CEO)** joined CohBar in 2016. Previously CBO of Ambrx, Inc and CEO of Kalypsys Inc. he has completed over 20 major transactions between Biotech and Pharma. Mr. Allen earned an MBA from the Australian Graduate School of Management and a B.Sc. from the University of Sydney.

**Kenneth C. Cundy Ph.D. (CSO)** joined CohBar in 2014. Previously CSO at Xenoport, Inc. (NASDAQ: XNPT) and Senior Director of Biopharmaceuticals at Gilead Sciences, Inc. (NASDAQ: GILD), Dr. Cundy earned a PhD. in Pharmaceutical Sciences from the University of Kentucky, with postdoctoral training in Biochemistry at the University of California, Berkeley. He holds over 150 US and int’l patents.

**Jon L. Stern MBA (COO)** joined CohBar in 2013. Mr. Stern has over 30 years experience in senior management roles and has founded three companies. Mr. Stern earned an MBA from the University of Southern California.

**Jeff Biunno CPA, MBA (CFO)** joined CohBar in 2013. He previously served as Chief Financial Officer of ManagelQ, Inc. and Corporate Controller for Novadigm, Inc. (NASDAQ: NVDM). Mr. Biunno earned an MBA from Montclair State University.

### Forward Looking Statements

Statements contained herein concerning future plans, prospects and expectations, including statements regarding potential development or use of therapeutics from the Company’s preclinical pipeline, are forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act. Forward-looking statements are subject to known and unknown risks and uncertainties, many of which may be beyond our control. We caution you that the forward-looking information presented herein is not a guarantee of future events, and that actual events may differ materially from those made in or suggested by the forward-looking information contained in this document. These assumptions, risks and uncertainties are described in detail in our Annual Report on Form 10-K for the year-ended December 31, 2015 and in our registration statements, reports and other filings with the Securities and Exchange Commission and applicable Canadian securities regulators, which are available on our website, and at [www.sec.gov](http://www.sec.gov) or [www.sedar.com](http://www.sedar.com).